Bone marrow-derived and peritoneal macrophages have different inflammatory response to oxLDL and M1/M2 marker

Line S Bisgaard1,2, Christina K Mogensen2, Alexander Rosendahl2,3

  • 1Dept. of Biomedical Sciences, University of Copenhagen, Denmark.

Scientific Reports
|October 14, 2016
PubMed

Insights

Peritoneal macrophages (PEMs) and bone marrow-derived macrophages (BMDMs) exhibit distinct phenotypes and differ from aortic macrophages in atherosclerosis. Their inflammatory and lipid profiles vary, impacting their roles in disease progression.

Area of Science:

  • Immunology
  • Cardiovascular Research
  • Cell Biology

Background:

  • Macrophages are key immune cells with diverse phenotypes, including pro-inflammatory (M1-like) and remodeling (M2-like) subsets.
  • Understanding macrophage heterogeneity is crucial for studying inflammatory diseases like atherosclerosis.

Purpose of the Study:

  • To compare the M1/M2 phenotype, inflammatory status, and lipid metabolism of peritoneal macrophages (PEMs) and bone marrow-derived macrophages (BMDMs).
  • To determine if PEMs or BMDMs resemble aortic macrophages found in ApoE-/- mice with atherosclerosis.

Main Methods:

  • Protein and mRNA expression analysis of M1/M2 markers and lipid metabolism genes.
  • Flow cytometry on whole aortas and isolated lesions from ApoE-/- mice.
  • Cholesterol loading experiments on PEMs and BMDMs.

Main Results:

  • BMDMs displayed an M2-like profile (CD206highCD11c low), while PEMs showed low CD206 and CD11c expression.
  • Cholesterol loading increased CD11c and decreased MCP-1 secretion in BMDMs, but increased CD11c and MCP-1 secretion in PEMs.
  • Aortic macrophages in advanced atherosclerosis showed an M2-like phenotype, with decreased M2 markers and lipid metabolism gene expression in advanced lesions.

Conclusions:

  • PEMs and BMDMs are phenotypically distinct and do not fully recapitulate the characteristics of macrophages within atherosclerotic lesions.
  • Macrophage phenotype and function within atherosclerotic lesions change with disease severity, showing a shift away from M2-like markers and lipid metabolism genes in advanced stages.